The future of perioperative therapy in advanced renal cell carcinoma: How can we PROSPER?

Hiten D. Patel, Maneka Puligandla, Brian M. Shuch, Bradley C. Leibovich, Anil Kapoor, Viraj A. Master, Charles G. Drake, Daniel Y.C. Heng, Primo N. Lara, Toni K. Choueiri, Deborah Maskens, Eric A. Singer, Scott E. Eggener, Robert S. Svatek, Walter M. Stadler, Suzanne Cole, Sabina Signoretti, Rajan T. Gupta, Marc Dror Michaelson, David F. McDermottDavid Cella, Lynne I. Wagner, Naomi B. Haas, Michael A. Carducci, Lauren C. Harshman, Mohamad E. Allaf

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

While many patients with early stage kidney cancer can be cured by removal of the tumor and kidney ('nephrectomy'), upward of 40% of patients can recur due to microscopic spread of the cancer prior to surgery. Adding anticancer drugs that are effective in the metastatic setting to surgery has potential to eliminate the microscopic disease and increase cure rates. The PROSPER renal cell carcinoma study is testing whether adding nivolumab, a drug that engages the immune system to better recognize, fight and eliminate the cancer, will improve disease control over surgery alone. Nivolumab will be given before and after surgery to see if it reduces the chance of the disease returning and decreases death from kidney cancer compared with patients receiving surgery only.

Original languageEnglish (US)
Pages (from-to)1683-1695
Number of pages13
JournalFuture Oncology
Volume15
Issue number15
DOIs
StatePublished - May 2019

Fingerprint

Renal Cell Carcinoma
Kidney Neoplasms
Therapeutics
Neoplasms
Nephrectomy
Pharmaceutical Preparations
Immune System
Kidney
nivolumab

Keywords

  • clinical trial
  • kidney cancer
  • neoadjuvant therapy
  • nephrectomy
  • nivolumab
  • perioperative
  • presurgical
  • PROSPER RCC
  • renal cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Patel, H. D., Puligandla, M., Shuch, B. M., Leibovich, B. C., Kapoor, A., Master, V. A., ... Allaf, M. E. (2019). The future of perioperative therapy in advanced renal cell carcinoma: How can we PROSPER? Future Oncology, 15(15), 1683-1695. https://doi.org/10.2217/fon-2018-0951

The future of perioperative therapy in advanced renal cell carcinoma : How can we PROSPER? / Patel, Hiten D.; Puligandla, Maneka; Shuch, Brian M.; Leibovich, Bradley C.; Kapoor, Anil; Master, Viraj A.; Drake, Charles G.; Heng, Daniel Y.C.; Lara, Primo N.; Choueiri, Toni K.; Maskens, Deborah; Singer, Eric A.; Eggener, Scott E.; Svatek, Robert S.; Stadler, Walter M.; Cole, Suzanne; Signoretti, Sabina; Gupta, Rajan T.; Michaelson, Marc Dror; McDermott, David F.; Cella, David; Wagner, Lynne I.; Haas, Naomi B.; Carducci, Michael A.; Harshman, Lauren C.; Allaf, Mohamad E.

In: Future Oncology, Vol. 15, No. 15, 05.2019, p. 1683-1695.

Research output: Contribution to journalArticle

Patel, HD, Puligandla, M, Shuch, BM, Leibovich, BC, Kapoor, A, Master, VA, Drake, CG, Heng, DYC, Lara, PN, Choueiri, TK, Maskens, D, Singer, EA, Eggener, SE, Svatek, RS, Stadler, WM, Cole, S, Signoretti, S, Gupta, RT, Michaelson, MD, McDermott, DF, Cella, D, Wagner, LI, Haas, NB, Carducci, MA, Harshman, LC & Allaf, ME 2019, 'The future of perioperative therapy in advanced renal cell carcinoma: How can we PROSPER?', Future Oncology, vol. 15, no. 15, pp. 1683-1695. https://doi.org/10.2217/fon-2018-0951
Patel HD, Puligandla M, Shuch BM, Leibovich BC, Kapoor A, Master VA et al. The future of perioperative therapy in advanced renal cell carcinoma: How can we PROSPER? Future Oncology. 2019 May;15(15):1683-1695. https://doi.org/10.2217/fon-2018-0951
Patel, Hiten D. ; Puligandla, Maneka ; Shuch, Brian M. ; Leibovich, Bradley C. ; Kapoor, Anil ; Master, Viraj A. ; Drake, Charles G. ; Heng, Daniel Y.C. ; Lara, Primo N. ; Choueiri, Toni K. ; Maskens, Deborah ; Singer, Eric A. ; Eggener, Scott E. ; Svatek, Robert S. ; Stadler, Walter M. ; Cole, Suzanne ; Signoretti, Sabina ; Gupta, Rajan T. ; Michaelson, Marc Dror ; McDermott, David F. ; Cella, David ; Wagner, Lynne I. ; Haas, Naomi B. ; Carducci, Michael A. ; Harshman, Lauren C. ; Allaf, Mohamad E. / The future of perioperative therapy in advanced renal cell carcinoma : How can we PROSPER?. In: Future Oncology. 2019 ; Vol. 15, No. 15. pp. 1683-1695.
@article{c656fa258bd24005acdf709a2714e9c9,
title = "The future of perioperative therapy in advanced renal cell carcinoma: How can we PROSPER?",
abstract = "While many patients with early stage kidney cancer can be cured by removal of the tumor and kidney ('nephrectomy'), upward of 40{\%} of patients can recur due to microscopic spread of the cancer prior to surgery. Adding anticancer drugs that are effective in the metastatic setting to surgery has potential to eliminate the microscopic disease and increase cure rates. The PROSPER renal cell carcinoma study is testing whether adding nivolumab, a drug that engages the immune system to better recognize, fight and eliminate the cancer, will improve disease control over surgery alone. Nivolumab will be given before and after surgery to see if it reduces the chance of the disease returning and decreases death from kidney cancer compared with patients receiving surgery only.",
keywords = "clinical trial, kidney cancer, neoadjuvant therapy, nephrectomy, nivolumab, perioperative, presurgical, PROSPER RCC, renal cell carcinoma",
author = "Patel, {Hiten D.} and Maneka Puligandla and Shuch, {Brian M.} and Leibovich, {Bradley C.} and Anil Kapoor and Master, {Viraj A.} and Drake, {Charles G.} and Heng, {Daniel Y.C.} and Lara, {Primo N.} and Choueiri, {Toni K.} and Deborah Maskens and Singer, {Eric A.} and Eggener, {Scott E.} and Svatek, {Robert S.} and Stadler, {Walter M.} and Suzanne Cole and Sabina Signoretti and Gupta, {Rajan T.} and Michaelson, {Marc Dror} and McDermott, {David F.} and David Cella and Wagner, {Lynne I.} and Haas, {Naomi B.} and Carducci, {Michael A.} and Harshman, {Lauren C.} and Allaf, {Mohamad E.}",
year = "2019",
month = "5",
doi = "10.2217/fon-2018-0951",
language = "English (US)",
volume = "15",
pages = "1683--1695",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "15",

}

TY - JOUR

T1 - The future of perioperative therapy in advanced renal cell carcinoma

T2 - How can we PROSPER?

AU - Patel, Hiten D.

AU - Puligandla, Maneka

AU - Shuch, Brian M.

AU - Leibovich, Bradley C.

AU - Kapoor, Anil

AU - Master, Viraj A.

AU - Drake, Charles G.

AU - Heng, Daniel Y.C.

AU - Lara, Primo N.

AU - Choueiri, Toni K.

AU - Maskens, Deborah

AU - Singer, Eric A.

AU - Eggener, Scott E.

AU - Svatek, Robert S.

AU - Stadler, Walter M.

AU - Cole, Suzanne

AU - Signoretti, Sabina

AU - Gupta, Rajan T.

AU - Michaelson, Marc Dror

AU - McDermott, David F.

AU - Cella, David

AU - Wagner, Lynne I.

AU - Haas, Naomi B.

AU - Carducci, Michael A.

AU - Harshman, Lauren C.

AU - Allaf, Mohamad E.

PY - 2019/5

Y1 - 2019/5

N2 - While many patients with early stage kidney cancer can be cured by removal of the tumor and kidney ('nephrectomy'), upward of 40% of patients can recur due to microscopic spread of the cancer prior to surgery. Adding anticancer drugs that are effective in the metastatic setting to surgery has potential to eliminate the microscopic disease and increase cure rates. The PROSPER renal cell carcinoma study is testing whether adding nivolumab, a drug that engages the immune system to better recognize, fight and eliminate the cancer, will improve disease control over surgery alone. Nivolumab will be given before and after surgery to see if it reduces the chance of the disease returning and decreases death from kidney cancer compared with patients receiving surgery only.

AB - While many patients with early stage kidney cancer can be cured by removal of the tumor and kidney ('nephrectomy'), upward of 40% of patients can recur due to microscopic spread of the cancer prior to surgery. Adding anticancer drugs that are effective in the metastatic setting to surgery has potential to eliminate the microscopic disease and increase cure rates. The PROSPER renal cell carcinoma study is testing whether adding nivolumab, a drug that engages the immune system to better recognize, fight and eliminate the cancer, will improve disease control over surgery alone. Nivolumab will be given before and after surgery to see if it reduces the chance of the disease returning and decreases death from kidney cancer compared with patients receiving surgery only.

KW - clinical trial

KW - kidney cancer

KW - neoadjuvant therapy

KW - nephrectomy

KW - nivolumab

KW - perioperative

KW - presurgical

KW - PROSPER RCC

KW - renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85064714672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064714672&partnerID=8YFLogxK

U2 - 10.2217/fon-2018-0951

DO - 10.2217/fon-2018-0951

M3 - Article

C2 - 30968729

AN - SCOPUS:85064714672

VL - 15

SP - 1683

EP - 1695

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 15

ER -